Zealand Amylin Analog

A long-acting amylin analog studied as a weight-management monotherapy with a potentially gentler tolerability profile than incretins.

Zealand Amylin Analog is classified as a long-acting amylin analog. Its current development status is: phase 2 clinical trials. Most of the evidence is preclinical. Human data is early, small, or absent for the uses commonly discussed.

The Peptide Institute tracks Zealand Amylin Analog because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.